Market Cap (In SEK)
165.28 Million
Revenue (In SEK)
50.92 Million
Net Income (In SEK)
-7.45 Million
Avg. Volume
100.19 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.351-0.748
- PE
- -
- EPS
- -
- Beta Value
- 1.331
- ISIN
- SE0007438577
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ms. Charlotte Fribert
- Employee Count
- -
- Website
- https://www.toleranzia.com
- Ipo Date
- 2015-12-16
- Details
- Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, the company develops tolerogens technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was founded in 2011 and is headquartered in Gothenburg, Sweden.
More Stocks
-
NAPRFNaspers Limited
NAPRF
-
000630
-
DSECF
-
SZHFFSojitz Corporation
SZHFF
-
NYAXNayax Ltd.
NYAX
-
603022
-
S56
-
YCQH